Harmony Biosciences Holdings Inc (HRMY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.04 is considered Undervalued compared with the five-year average of 16.52. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 65.11 to 98.13 according to relative valuation method. Compared to the current price of 28.90 USD , Harmony Biosciences Holdings Inc By Undervalued By 55.61%.

Relative Value

Fair Zone

65.11-98.13

Current Price：28.90

55.61%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Harmony Biosciences Holdings Inc (HRMY) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Harmony Biosciences Holdings Inc (HRMY) has a current Price-to-Book (P/B) ratio of 2.58. Compared to its 3-year average P/B ratio of 3.47, the current P/B ratio is approximately -25.77% higher. Relative to its 5-year average P/B ratio of 7.38, the current P/B ratio is about -65.09% higher. Harmony Biosciences Holdings Inc (HRMY) has a Forward Free Cash Flow (FCF) yield of approximately 13.79%. Compared to its 3-year average FCF yield of 11.11%, the current FCF yield is approximately 24.15% lower. Relative to its 5-year average FCF yield of 8.00%, the current FCF yield is about 72.48% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for HRMY competitors is 2010.73, providing a benchmark for relative valuation. Harmony Biosciences Holdings Inc Corp (HRMY.O) exhibits a P/S ratio of 2.23, which is -99.89% above the industry average. Given its robust revenue growth of 21.12%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of HRMY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of HRMY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is HRMY currently overvalued or undervalued?

Harmony Biosciences Holdings Inc (HRMY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.04 is considered Undervalued compared with the five-year average of 16.52. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 65.11 to 98.13 according to relative valuation method. Compared to the current price of 28.90 USD, Harmony Biosciences Holdings Inc is Undervalued By 55.61%.

What is Harmony Biosciences Holdings Inc (HRMY) fair value?

HRMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 65.11 to 98.13 according to relative valuation method.

How does HRMY's valuation metrics compare to the industry average?

The average P/S ratio for HRMY's competitors is 2010.73, providing a benchmark for relative valuation. Harmony Biosciences Holdings Inc Corp (HRMY) exhibits a P/S ratio of 2.23, which is -99.89% above the industry average. Given its robust revenue growth of 21.12%, this premium appears sustainable.

What is the current P/B ratio for Harmony Biosciences Holdings Inc (HRMY) as of Mar 03 2026?

As of Mar 03 2026, Harmony Biosciences Holdings Inc (HRMY) has a P/B ratio of 2.58. This indicates that the market values HRMY at 2.58 times its book value.

What is the current FCF Yield for Harmony Biosciences Holdings Inc (HRMY) as of Mar 03 2026?

As of Mar 03 2026, Harmony Biosciences Holdings Inc (HRMY) has a FCF Yield of 13.79%. This means that for every dollar of Harmony Biosciences Holdings Inc's market capitalization, the company generates 13.79 cents in free cash flow.

What is the current Forward P/E ratio for Harmony Biosciences Holdings Inc (HRMY) as of Mar 03 2026?

As of Mar 03 2026, Harmony Biosciences Holdings Inc (HRMY) has a Forward P/E ratio of 10.04. This means the market is willing to pay $10.04 for every dollar of Harmony Biosciences Holdings Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Harmony Biosciences Holdings Inc (HRMY) as of Mar 03 2026?

As of Mar 03 2026, Harmony Biosciences Holdings Inc (HRMY) has a Forward P/S ratio of 2.23. This means the market is valuing HRMY at $2.23 for every dollar of expected revenue over the next 12 months.

HRMY Valuation